Lanfil 15 Tablet DT contains Lansoprazole 15 mg, a proton pump inhibitor (PPI) used primarily for the treatment of acid-related gastrointestinal conditions. Lansoprazole acts by selectively inhibiting the H+/K+ ATPase enzyme system at the secretory surface of gastric parietal cells, thereby suppressing gastric acid secretion. This reduction in acid production promotes healing of erosive esophagitis, gastroesophageal reflux disease (GERD), and peptic ulcers, including duodenal and gastric ulcers. Lanfil 15 Tablet DT is also indicated for the management of Zollinger-Ellison syndrome and for the eradication of Helicobacter pylori infection when used in combination with appropriate antibiotics. The tablet is designed as a dispersible formulation, allowing for rapid dissolution in the oral cavity without the need for water, enhancing patient compliance, especially in those with swallowing difficulties. It is generally well-tolerated, with adverse effects being infrequent and mild, including headache, diarrhea, and abdominal discomfort. Lanfil 15 Tablet DT should be administered as directed by a healthcare professional, with dosage adjustments based on clinical response and specific patient needs. Caution is advised in patients with hepatic impairment, and long-term use should be monitored to avoid potential complications such as vitamin B12 deficiency or increased risk of gastrointestinal infections.